VOQUEZNA Inclusion in Express Scripts: Game Changer for GERD?

Phathom Pharmaceuticals brings relief to millions with the inclusion of its drug VOQUEZNA in Express Scripts’ national formularies

Phathom Pharmaceuticals announced that its innovative treatment for Erosive Esophagitis, a form of gastroesophageal reflux disease (GERD), is now accessible to an estimated 60 million individuals in the United States. VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), marks a major milestone in the field of Erosive GERD treatment. It represents the first new class of treatment for Erosive GERD to be made available in the U.S. in over 30 years. This breakthrough drug is sure to revolutionize the landscape of GERD treatment options.